New drug shows promise in preventing deadly blood clot relapses in japanese patients
NCT ID NCT04074187
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a drug called caplacizumab in 21 Japanese adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. Participants received caplacizumab alongside standard treatments like plasma exchange and steroids. The goal was to see if the drug could prevent the disease from coming back. Early results suggest it may help control the disorder, but larger studies are needed to confirm safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
caplacizumab
What this could lead to
If successful, this could offer a new treatment option to prevent life-threatening blood clots and relapses in Japanese patients with acquired TTP.
What could go wrong
This was a small, early-phase study with only 21 participants, so results may not apply to all patients. Side effects like bleeding are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 3920001
Kitakyushu-Shi, Japan
-
Investigational Site Number 3920002
Kumamoto, Japan
-
Investigational Site Number 3920003
Kurashiki-Shi, Japan
-
Investigational Site Number 3920005
Maebashi, Japan
-
Investigational Site Number 3920006
Sendai, Japan
-
Investigational Site Number 3920007
Kashihara-shi, Japan
-
Investigational Site Number 3920009
Iruma-Gun, Japan
-
Investigational Site Number 3920010
Kyoto, Japan
-
Investigational Site Number 3920011
Osaka, Japan
-
Investigational Site Number 3920013
Kawasaki-Shi, Japan
-
Investigational Site Number 3920014
Kanazawa, Japan
-
Investigational Site Number 3920015
Nagoya, Japan